How to titrate up safely on a GLP-1

TLDR. Standard GLP-1 titration is one dose level every four weeks: Wegovy at 0.25, 0.5, 1.0, 1.7 then 2.4 mg weekly; Zepbound at 2.5, 5, 7.5, 10, 12.5 then 15 mg weekly. The schedule is a default, not a law. Slow titration (6 to 8 weeks per step) is the right move for patients with severe GI side effects. Pausing at an earlier maintenance dose (Wegovy 1.7, Zepbound 10) is appropriate when efficacy is sufficient. Faster titration is rarely advised because the side-effect curve is dose-dependent. Your prescriber's job is to match the schedule to your tolerance, not the package insert.

The standard semaglutide and tirzepatide titration schedule is published in every prescribing information sheet: increase one dose level every 4 weeks until you reach the maintenance dose. This is what your program will default to.

For about 60-70% of patients, the standard schedule works. For the rest, slowing down or holding a dose makes the difference between continuing treatment and quitting. This post explains when and how.

Standard semaglutide titration (Wegovy / compounded)

Standard tirzepatide titration (Zepbound / compounded)

Signs the standard schedule is too aggressive

• Persistent nausea or vomiting more than 2 weeks after a dose increase
• Weight loss greater than 2.5lb (~1kg) per week, too fast, suggests body is in stress response
• Resting heart rate increase of more than 5-10 bpm
• Inability to eat enough to maintain protein intake (1g per kg)
• Persistent fatigue that doesn't resolve with adequate sleep

If any of these are present at your current dose, hold for an additional 2-4 weeks before escalating. There is no penalty for slow titration; your terminal weight loss outcome at 12 months is essentially the same whether you reached maintenance dose at week 16 or week 28.

Signs the standard schedule is too slow

• Minimal-to-no GI side effects after 4 weeks at current dose
• Weight loss less than 0.5lb (~0.2kg) per week at non-starting dose
• Subjective hunger has not changed

If all three are present, you may be a sub-responder at this dose. Faster titration is rarely the answer; switching from semaglutide to tirzepatide is usually more effective for non-responders. Talk to your prescriber.

When to dose-hold vs dose-down

Dose-hold: Stay at the current dose for an additional 2-4 weeks then reattempt the next escalation. Use when side effects are tolerable but persistent. Most common adjustment.

Dose-down: Drop back one level to the previously tolerated dose. Use when a recent escalation produced severe side effects. Rare but appropriate for severe vomiting, dehydration or persistent gastroparesis-like symptoms.

Stop entirely: Reserved for serious adverse events (pancreatitis, severe allergic reaction, persistent gastroparesis). Talk to your prescriber the same day.

Microdosing as a stop-gap

Some programs (notably Noom Med) offer microdose protocols starting at 0.1mg semaglutide instead of 0.25mg. There is no clinical trial evidence that microdosing produces better outcomes than standard titration in tolerant patients, but for patients who failed standard 0.25mg due to severe side effects, microdosing has anecdotal support as a way to extend tolerance.

Microdose is not a magic trick. The lower the starting dose, the longer titration takes, and weight loss correlates with dose reached. Use it as a tolerance bridge, not a permanent strategy.

The general rule

Slower titration costs almost nothing in terminal weight-loss outcomes. It costs a lot in side-effect-driven discontinuation. If you're not sure, hold a dose for an extra month. Your year-one weight loss number will be within 1-2 percentage points of the patient who pushed through the standard schedule.

Frequently asked questions

Can I slow down the standard GLP-1 titration?

Yes, when side effects warrant it. Many obesity-medicine prescribers will hold a dose for 6 to 8 weeks instead of the standard 4 if GI symptoms are severe. The FDA label schedule is a default. Slow titration is a recognized clinical option that does not change long-term outcomes meaningfully; it just buys tolerability.

Can I skip dose levels to get to maintenance faster?

Not advised. The side-effect curve is dose-dependent: jumping from 0.25 to 1.0 mg without the intermediate 0.5 mg step triples the rate of nausea and vomiting in real-world cohorts. The whole point of titration is to let receptor adaptation occur gradually. Faster is not better.

Do I have to escalate to the maximum dose?

No. Plenty of patients stop at Wegovy 1.7 mg or Zepbound 10 mg when efficacy is sufficient. Trial data shows progressive but diminishing returns at higher doses, and side-effect rates rise with each step. If you have hit your goal weight at 1.7 mg, there is no clinical reason to push to 2.4 mg.

What if I miss a dose during titration?

If less than 5 days late, take the dose and resume the schedule. If more than 5 days late, skip the missed dose and take the next scheduled one. If you miss more than 2 consecutive weeks at a titration step, consult your prescriber: you may need to step back to a lower dose to re-titrate.

How long until I reach the maintenance dose?

Standard titration is 16 weeks to reach Wegovy 2.4 mg or 20 weeks to reach Zepbound 15 mg. Slow titration adds 4 to 16 weeks to that. Maintenance is then indefinite; current evidence supports staying on the medication long-term for most patients who tolerate it.